Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 152 of the 155 references it cites were found in a registry or an index.

The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic

Geng, Leiluo, Lam, Karen S. L., Xu, Aimin · 2020 · Nature Reviews Endocrinology

Abstract

Fibroblast growth factor 21 (FGF21) is a stress-inducible hormone that has important roles in regulating energy balance and glucose and lipid homeostasis through a heterodimeric receptor complex comprising FGF receptor 1 (FGFR1) and β-klotho. Administration of FGF21 to rodents or non-human primates causes considerable pharmacological benefits on a cluster of obesity-related metabolic complications, including a reduction in fat mass and alleviation of hyperglycaemia, insulin resistance, dyslipidaemia, cardiovascular disorders and non-alcoholic steatohepatitis (NASH). However, native FGF21 is unsuitable for clinical use owing to poor pharmacokinetic and biophysical properties. A large number of long-acting FGF21 analogues and agonistic monoclonal antibodies for the FGFR1-β-klotho receptor complexes have been developed. Several FGF21 analogues and mimetics have progressed to early phases of clinical trials in patients with obesity, type 2 diabetes mellitus and NASH. In these trials, the primary end points of glycaemic control have not been met, whereas substantial improvements were observed in dyslipidaemia, hepatic fat fractions and serum markers of liver fibrosis in patients with NASH. The complexity and divergence in pharmacology and pathophysiology of FGF21, interspecies variations in FGF21 biology, the possible existence of obesity-related FGF21 resistance and endogenous FGF21 inactivation enzymes represent major obstacles to clinical implementation of FGF21-based pharmacotherapies for metabolic diseases.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41574-020-0386-0

Cites

152 of 152 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 155 references

Cited by

See all 625

Metadata

Authors
Geng, L., Lam, K. S. L., & Xu, A.
Affiliations
University of Hong Kong (HK)
Corresponding author
Xu, Aimin
Venue
Nature Reviews Endocrinology
Published
2020-08-06
Volume
16
Issue
11
Pages
654-667
ISSN
  • 1759-5029 (ISSN-L)
  • 1759-5037
OpenAlex
W3047314584
Cited by
607
References
155
Citations by year
2026: 97 · 2025: 115 · 2024: 128 · 2023: 114 · 2022: 87 · 2021: 60 · 2020: 6
FWCI
6.39
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
FGF21, FGF21 analogues, FGF receptor 1, β-Klotho, obesity, type 2 diabetes, nonalcoholic steatohepatitis, dyslipidemia, insulin resistance, hyperglycemia, monoclonal antibodies, FGF21 resistance, interspecies variation, metabolic disorders, drug development
MeSH terms
Lipidomics, Animals, Clinical Trials as Topic, Fibroblast Growth Factors, Humans, Metabolic Diseases, Species Specificity, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. https://app.cochat.ai/papers/10.1038/s41574-020-0386-0
The paper
Geng, L., Lam, K. S. L., & Xu, A. (2020). The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-020-0386-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.